glp 1 and multiple sclerosis Repurposing glucagon-like peptide-1 receptor agonists for the treatment of neurodegenerative disorders GLP-1s and Multiple Sclerosis -

Tulsi Kotecha is the founder and medical director of Refine by Tulsi, a physician-led aesthetic and wellness practice with locations in Lincoln Park and Logan Square, Chicago

Tirzepatide produces greater weight loss and may have stronger effects on insulin sensitivity

The most severe symptoms associated with biotin deficiency and profound biotinidase gene defects are the result of the accumulation of toxic metabolic intermediates

Further work is required to determine the impact of combinations of these therapies on heart and kidney endpoints in patients with diabetes

Alternative Titration Approaches Some protocols use more aggressive titration, increasing every 1-2 weeks for faster dose finding

10.1016/j.isci.2021.103312 Iscience